Navigation Links
Akela Pharma initiates its first abuse deterrent opioid Phase I clinical trial
Date:3/6/2008

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, March 6 /PRNewswire-FirstCall/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it has started its first EDACS(TM) product Phase I clinical trial. EDACS(TM) is Akela's patent pending platform technology to prevent abuse of controlled substances.

This Phase I trial for the first EDACS(TM) based product is an open-label, randomized, single-dose, cross-over study investigating the pharmacokinetics and safety of 3 different extended release formulations of a well-known opioid product compared to the same opioid drug immediate release formulation. The study will be carried out in 12 healthy subjects, and the results are expected to be available in Q3/2008.

"The abuse of prescription drugs is approaching epidemic proportions in numerous countries. The costs to society associated with this abuse are tremendous. Akela has developed a platform technology to prevent the abuse of such substances by preventing the tampering of extended release dosage forms as well as unintentional dose dumping in alcohol. " said Dr. Halvor Jaeger, Chief Executive Officer of Akela Pharma Inc. "We believe that our platform technology is perfectly suited to meet the increasing market demand as well as regulatory pressure for abuse deterrent formulations."

About EDACS(TM):

EDACS(TM) is a patent pending platform technology which utilizes extrusion technology to prepare an insoluble matrix containing dispersed drug which can be shaped into tablets. The matrix is water insoluble, slightly soluble in ethanol, not friable, does not break on compression or allow for crushing and inhalation and does not allow for dissolution and injection.

About Akela Pharma Inc.:

Akela Pharma is an integrated drug development company
'/>"/>

SOURCE Akela Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
2. Akela Pharma provides corporate update
3. Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial
4. Akela Pharma reports results for third quarter of fiscal 2007
5. AKELA Pharma Inc. announces U.S. public offering and proposed listing
6. Akela Pharma Inc. Completes Share Consolidation
7. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
8. MinuteClinic Hits 500th Clinic Mark; New Locations Open in Dallas, Los Angeles and Orlando CVS/pharmacy Stores
9. Notice of Bradmer Pharmaceuticals Conference Call
10. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
11. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 Footwear etc. is pleased ... Vista Collection of sandals containing cork footbeds. Known for its ... consistently good sales for many years, and with this new ... summer. , Dansko Shoes and Sandals are ... Collection is no exception. Containing leather and patent leather uppers ...
(Date:5/23/2013)... May 23, 2013 Following the recent ... UK internet users, the security team at idcloak Technologies ... safeguards against this or any web-born malware. Gill-Chris ... technology provides far better privacy and security ... underlined that even the best AV software cannot be ...
(Date:5/23/2013)... 2013 Long-Term Care Insurance shopping ... rate at which applicants for Long Term Care Insurance are ... , The decision to buy a Long Term Care ... willing and able to purchase protection are increasingly being turned ... any price. A variety of chronic conditions appear to ...
(Date:5/23/2013)... 2013 When Teachers Notebook reached out ... raise funds for the Moore, OK tornado victims, they ... items that could be sold for around $10.00 with ... at Teachers Notebook were overwhelmed by the response from ... of materials within the first 12 hours of the ...
(Date:5/23/2013)... 2013 AttorneyOne.com, a recognized authority on ... actively providing expert opinion in view of the recent ... According to court documents, on March 5, 2013 a ... (case no. 3:2013cv50102) alleging that her husband suffered massive ... Pharmaceuticals, is mainly used as a blood thinner for ...
Breaking Medicine News(10 mins):Health News:Footwear etc. Announces the New Collection of Dansko Cork Sandals 2Health News:Effective virus protection without anti-virus software, identifies idcloak 2Health News:More Baby Boomers Rejected by Long Term Care Insurance Companies 2Health News:More Baby Boomers Rejected by Long Term Care Insurance Companies 3Health News:Teachers Rally to Raise Funds for Moore Tornado Victims 2Health News:New Lawsuit on Pradaxa Brain Hemorrhage: Now, AttorneyOne Can Provide Advice 2
... ... chairman of the board of directors for PerfectServe, a clinical communications company currently serving ... ... Gene Barduson was recently named executive chairman of the board of directors for ...
... , , BOCA RATON, ... the market leader in all-natural herbal and homeopathic remedies for ... as their PR firm of record. The company,s two brands, ... provide complete lines of safe, scientifically-tested, guaranteed products that promote ...
... AllegroMedical.com partners with ... ... help find a cure for spinal cord injury: The online retailer of medical supplies ... is a forward-thinking manufacturer of catheters. In an effort to facilitate finding a cure ...
... more emotional and behavioral difficulties when compared to other ... most when a parent is deployed overseas, according to ... having a parent deployed for a longer period of ... with emotional problems were important factors associated with whether ...
... , , Consumers ... SILVER SPRING, Md., Dec. 6 The U.S. Food and Drug ... San Antonio Bay on or after Nov. 16 due to reports ... from this area, which is located on the Gulf of Texas. ...
... College of Wisconsin, in Milwaukee, found a substantial variation ... disease complications in children. Barriers to its use on ... identified. The study led by Amanda M. Brandow, ... College and Children,s Research Institute at the Children,s Hospital ...
Cached Medicine News:Health News:Gene Barduson Named Chairman of PerfectServe Board of Directors 2Health News:Native Remedies and PetAlive.com Hires TransMedia Group to Herald Herbal for People and Pets 2Health News:Online Medical Supply Superstore Adds Cure Catheters to Product Mix 2Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 2Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 3Health News:FDA, CDC, and States Investigating Norovirus Illnesses Linked to Oysters 2Health News:New study finds barriers to pain treatment in children with sickle cell disease 2
(Date:5/22/2013)... , May 22, 2013 The new 13-valent ... as the previous version used prior to 2010, the ... Permanente study published today in Vaccine. The ... beginning in 2010 after a series of trials. These ... range of pneumococcal types than the previously used PCV7, ...
(Date:5/22/2013)... YORK , May 22, 2013 ... LLP is investigating claims on behalf of investors of ... ISRG ) (CUSIP: 46120E602) who purchased Intuitive ... 18, 2013 (the "Class Period"). Such investors are advised ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ...
(Date:5/22/2013)... May 22, 2013 Hemoglobin A1C levels ... with Type 2 diabetes, while modest improvements in ... outcomes and can lead to substantial healthcare cost ... International Society for Pharmacoeconomics and Outcomes Research (ISPOR) ... studies, sponsored by Valeritas, makers of the V-Go ...
Breaking Medicine Technology:Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6
... , , ... OPTR ) today announced that new data highlighting ... vancomycin-resistant enterococci (VRE) acquisition from Optimer,s North American phase 3 ... Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. , ...
... HONG KONG, Sept. 15 Data from multiple clinical trials ... stent, and preclinical data from Combo Bio-engineered Sirolimus Eluting Stent ... symposium, TCT 2009, in San Francisco. , , ... Center in Amsterdam will provide the final 12-month outcomes from ...
Cached Medicine Technology:Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 2Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 3Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 5Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 6Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2009 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2009 3
The 920M PLUS handheld pulseoximeter provides on-the-spot bloodoximetry and heart rate readings....
Rad-5 signal extraction pulse oximeter™...
... 3100 is a small, lightweight ... worn comfortably on the patients ... activities and for overnight studies, ... WristOx is intended to give ...
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
Medicine Products: